Globally, dementia is the 5th leading cause of death and #AlzheimersDisease (AD) the 4th leading cause of disability-adjusted life-years lost in persons aged 75 years and older.² This year‘s motto at the Alzheimer Europe Conference in Geneva was “New horizons – Innovating for dementia“. We were amazed to hear about the latest innovations around AD and look forward to next year! #AlzheimersAwareness #34AEC
Lilly Neuroscience International
Pharmaceutical Manufacturing
Channel for the Professional Neuroscience Community. Follow us for information on Alzheimer’s Disease and Neuroscience.
About us
Lilly unites caring with discovery to make life better for people around the world. When you engage with Lilly on LinkedIn (and any other of Lilly's social media channels), you are agreeing to these Community Guidelines in addition to the Terms and Conditions or other legal notices provided by Lilly and those of LinkedIn.
- Website
-
https://e.lilly/4bO0nFJ
External link for Lilly Neuroscience International
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
Updates
-
Only 2 weeks until #CTAD24 kicks off in Madrid! We hope you are as excited as we are to join clinicians and researchers to discuss the latest scientific developments in #AlzheimersDisease #AlzheimersAwareness
-
-
Depression is the second most common neuropsychiatric symptom in #AlzheimersDisease.¹ Diagnosing late-life depression, particularly in those affected by dementia, is complicated because they can be clinically indistinguishable.¹ #AlzheimersAwareness #WorldMentalHealthDay #34AEC
-
-
As the global population ages, dementias, including #AlzheimersDisease, present some of the most urgent health challenges of our time¹,². Lilly welcomes the discussions taking place today on the sidelines of the 2024 G7 Health Ministerial meeting in Ancona, Italy. We look forward to a productive dialogue on the readiness of health care systems for person-centered care and national advancements in improving the Alzheimer’s disease care pathway.
-
-
Today marks the start of the Alzheimer Europe Conference in Geneva. Over the next few days there will be many clinical insights and research highlights discussed. We are ready and set-up at booth number 5. #34AEC #AlzheimersDisease #AlzheimersAwareness
-
-
One of the topics at the LausanneXI workshop is the #AlzheimersDisease diagnostic patient journey. Dr. Frances-Catherine Quevenco, participated in a panel discussion today pointing out: Biomarkers enable a more timely and accurate diagnosis for patients.¹,² #AlzheimersAwareness
-
-
Today is the start of the 11ᵗʰ annual Lausanne Workshop. For three days the dialogue on how to best innovate in #AlzheimersDisease prevention, diagnosis, management, and care is open. We are proud to take part in this important discussion. #AlzheimersAwareness
-
-
It’s #𝐓𝐢𝐦𝐞𝐓𝐨𝐀𝐜𝐭𝐎𝐧𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫𝐬 this #𝐖𝐨𝐫𝐥𝐝𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫𝐬𝐌𝐨𝐧𝐭𝐡. 50% of the costs for dementia are related to informal care.⁵ Through prioritizing the early and accurate detection of #𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫𝐬𝐃𝐢𝐬𝐞𝐚𝐬𝐞 we have a better chance to reduce the burden on informal care partners and delay the need for residential care services. #𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫𝐬𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬
-
-
Over 50% of care partners globally say their health has suffered as a result of their caring responsibilities, even whilst expressing positive sentiments about their role.¹ It’s #𝐓𝐢𝐦𝐞𝐓𝐨𝐀𝐜𝐭𝐎𝐧𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫𝐬 to prioritize the early and accurate detection of Alzheimer’s disease and alleviate the pressures faced by care partners worldwide. #𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫𝐬𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬
-